IMODIUM A-D (loperamide hydrochloride) by Johnson & Johnson is mechanism of action in vitro and animal studies show that loperamide hydrochloride capsules act by slowing intestinal motility and by affecting water and electrolyte movement through the bowel. First approved in 1988.
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
IMODIUM A-D is a loperamide hydrochloride oral solution indicated for acute diarrhea management in adults and children. It works by binding to opiate receptors in the gut wall, inhibiting acetylcholine and prostaglandin release to reduce peristalsis, increase intestinal transit time, and strengthen anal sphincter tone.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and focus shift toward cost management and market defense strategies.
Mechanism of Action In vitro and animal studies show that loperamide hydrochloride capsules act by slowing intestinal motility and by affecting water and electrolyte movement through the bowel. Loperamide binds to the opiate receptor in the gut wall. Consequently, it inhibits the release of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Combination Caplet With Loperamide Hydrochloride and Simethicone, and Imodium Express Tablets-lyophilizate Coadministered With Espumisan Capsule in Healthy Volunteers
Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence
Working on IMODIUM A-D offers stability in a mature, established OTC brand but limited growth trajectory due to approaching LOE and generic competition. Career value lies in commercial execution, customer relationship management, and defending market share rather than innovation or expansion.
Worked on IMODIUM A-D at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.